6 days ago
Women's Health Diagnostics Market Hits $14.6 Billion-Kalorama Information Report Reveals Key Growth Drivers to 2030
Comprehensive analysis reveals emerging opportunities in imaging, molecular diagnostics, and AI-driven tools as women's health takes center stage in global care strategies.
ARLINGTON, Va., July 17, 2025 /PRNewswire/ — Kalorama Information, a leading healthcare market research firm, has released its latest report, Women's Health Diagnostic Markets: Global Outlook and Forecast to 2030. This in-depth analysis examines the current and projected global markets for diagnostic tests uniquely relevant to women's health, offering vital insights for diagnostic companies, investors, and healthcare stakeholders seeking to capitalize on evolving clinical and consumer needs.
As global life expectancy for women continues to rise—and as women account for over 75% of healthcare decision-making in U.S. households—the report emphasizes a critical shift in medical diagnostics toward more personalized, sex-specific tools. Diagnostics are rapidly becoming the backbone of this transformation, enabling earlier detection, better outcomes, and more cost-effective care across the female lifespan.
'The global market for women's health test products is estimated to be worth $14.6 billion in 2024. This arena—once confined to obstetrics and gynecology—now spans specialties such as urology, maternal-fetal medicine, autoimmune and genetic disease,' said Justin Saeks, Senior Analyst at Kalorama Information. 'Diagnostics are essential to connecting patients to the right treatment at the right time, yet they remain one of the most cost-efficient parts of the healthcare system.'
Key Takeaways from the Report
Rising Global Adoption of NIPT: Non-invasive prenatal testing is now recommended for all U.S. pregnancies and is gaining ground globally. North America accounts for 44% of global NIPT revenues and is projected to grow at 8%+ CAGR through 2029.
Mammography Market on the Rise: Driven by widespread breast cancer screening, the mammography systems segment—dominated by digital technology—is forecast to grow at a mid-single-digit CAGR through 2030.
AI Transforms Diagnostic Imaging: Advances in deep learning are fueling the growth of computer-aided detection (CAD) tools, projected to expand by nearly 7% annually.
Diagnostics Drive Over 70% of Medical Decisions, yet account for less than 5% of total healthcare costs—highlighting a high-impact, under-leveraged sector for innovation and investment.
What's Inside the Report
The report offers detailed segmentation and forecasts across major diagnostic categories:
Imaging: Mammography, OB/GYN ultrasound, CADe/CADx
Genetic and Prenatal Testing: NIPT, carrier screening
Sexually Transmitted and Infectious Disease: HPV, TORCH, UTI diagnostics
Fertility & Pregnancy: POC and lab-based fertility, ovulation, pregnancy testing
Cancer and Autoimmune: Pap tests, ovarian cancer biomarkers, autoimmune immunoassays
Preventive Diagnostics: Bone densitometry, colposcopy systems
Companies Profiled: Becton Dickinson (BD), Hologic, GE HealthCare, Roche, Siemens Healthineers, Thermo Fisher Scientific, and emerging players across key sectors.
Who Should Read This Report
This report is a must-read for:
IVD and Device Manufacturers planning next-gen products in imaging, POC, or molecular diagnostics
Pharma and Biotech Firms seeking companion diagnostics for women-targeted therapies
Investors and M&A Teams identifying high-growth diagnostic segments
Healthcare Providers and Policymakers aiming to close the gap in women's health equity
Commercial and Strategy Leaders aligning messaging, product roadmaps, and reimbursement strategies
Availability & Contact Information
Explore the report:
Women's Health Diagnostic Markets: Global Outlook and Forecast to 2030 is available now from Kalorama Information. View Table of Contents / Purchase Report
For inquiries and custom consultations:Sheri Davie – Sales
For media inquiries:Richa Singh – VP, Strategic & Insights
About Kalorama Information
Kalorama Information, part of Science and Medicine Group, is a premier source for healthcare market intelligence. For over 25 years, Kalorama has delivered trusted insights on in vitro diagnostics (IVD), clinical testing, and emerging medical technologies, including its industry-leading title, The Worldwide Market for In Vitro Diagnostic Tests.
To learn more, visit:
